Overview

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of Ursofalk 500 mg tablets versus Ursofalk 500 mg capsules in the treatment of Primary Biliary Cirrhosis (PBC).
Phase:
Phase 4
Details
Lead Sponsor:
Dr. Falk Pharma GmbH
Treatments:
Ursodeoxycholic Acid